Inventor · disambiguated record
Frederic Triebel
Also filed as: TRIEBEL FREDERIC · TRIEBEL FRÉDÉRIC
33 granted patents·21 pending applications·813 citations·filing 1995–2025
98Inventor score
Top patents by PatentIndex Score
54 records- 0198US10711060B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Jul 14, 2020·29 cites·5 claims
- 0296US9908936B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Mar 6, 2018·23 cites·30 claims
- 0393US10940181B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2020·Granted Mar 9, 2021·3 cites·9 claims
- 0493US9244059B2Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune diseaseTRIEBEL FREDERIC·Filed 2010·Granted Jan 26, 2016·104 cites·5 claims
- 0593US5773578AProteins produced by human lymphocytes, DNA sequence encoding these proteins and their pharmaceutical and biological useINST NAT SANTE RECH MED·Filed 1995·Granted Jun 30, 1998·103 cites·2 claims
- 0689US10874713B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2016·Granted Dec 29, 2020·4 cites·17 claims
- 0789US6410509B1Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatmentROUSSY INST GUSTAVE·Filed 2000·Granted Jun 25, 2002·23 cites·22 claims
- 0889US6143273ATherapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 proteinROUSSY INST GUSTAVE·Filed 1998·Granted Nov 7, 2000·80 cites·5 claims
- 0987US5976877AProteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological usesINST NAT SANTE RECH MED·Filed 1995·Granted Nov 2, 1999·69 cites·6 claims
- 1086US12214012B2Combined preparations for the treatment of cancerIMMUTEP SAS·Filed 2020·Granted Feb 4, 2025·1 cites·12 claims
- 1186US11684654B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2020·Granted Jun 27, 2023·1 cites·10 claims
- 1286US8425897B2Compositions containing LAG-3 and cells that secrete GM-CSF and methods of useJOOSS KARIN·Filed 2008·Granted Apr 23, 2013·5 cites·6 claims
- 1385US10736940B2Combined preparations for the treatment of cancerIMMUTEP SAS·Filed 2014·Granted Aug 11, 2020·3 cites·40 claims
- 1485US9579382B2Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune responseTRIEBEL FRÉDÉRIC·Filed 2008·Granted Feb 28, 2017·9 cites·9 claims
- 1585US7294712B2Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic usesAVENTIS PHARMA SA·Filed 2002·Granted Nov 13, 2007·13 cites·5 claims
- 1685US5874250ADNA encoding for a protein containing the extracellular domain of lymphocyte activation gene 3INST NAT SANTE RECH MED·Filed 1995·Granted Feb 23, 1999·52 cites·10 claims
- 1784US11583582B2Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune responseIMMUTEP·Filed 2019·Granted Feb 21, 2023·1 cites·11 claims
- 1882US10232038B2Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune responseIMMUTEP·Filed 2017·Granted Mar 19, 2019·3 cites·17 claims
- 1982US5955300ASoluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodiesROUSSY INST GUSTAVE·Filed 1995·Granted Sep 21, 1999·35 cites·10 claims
- 2082US2023330182A1Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2023·Application pending·0 cites
- 2182US2025127856A1Combined preparations for the treatment of cancerIMMUTEP SAS·Filed 2024·Application pending·0 cites
- 2281US7109026B2Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatmentAPPLIED RESEARCH SYSTEMS·Filed 2002·Granted Sep 19, 2006·9 cites·5 claims
- 2381USRE38313ESoluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodiesROUSSY INST GUSTAVE·Filed 1995·Granted Nov 11, 2003·49 cites·15 claims
- 2479US6482925B1Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutantsAPPLIED RESEARCH SYSTEMS·Filed 1997·Granted Nov 19, 2002·56 cites·6 claims
- 2579US2023074746A1Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2022·Application pending·0 cites
- 2679US2024301055A1Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune diseaseIMMUTEP·Filed 2023·Application pending·0 cites
- 2778US2023149541A1Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune responseIMMUTEP·Filed 2023·Application pending·0 cites
- 2877US5700907ANucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic usesROUSSEL UCLAF·Filed 1995·Granted Dec 23, 1997·24 cites·6 claims
- 2975US2025382365A1Antibody molecules to lag-3 and uses thereofNOVARTIS AG·Filed 2025·Application pending·0 cites
- 3073US12252535B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Mar 18, 2025·0 cites·10 claims
- 3171US6875844B1Peptide compounds derived from a shifted ORF of the iCE geneROUSSY INST GUSTAVE·Filed 2000·Granted Apr 5, 2005·9 cites·7 claims
- 3271US2023272107A1Anti-lag-3 antibodiesIMMUTEP SAS·Filed 2023·Application pending·0 cites
- 3369US2021317210A1Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune diseaseIMMUTEP·Filed 2021·Application pending·0 cites
- 3467US6855802B1Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapyROUSSY INST GUSTAVE·Filed 1999·Granted Feb 15, 2005·26 cites·8 claims
- 3566US8709426B2Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic usesHERCEND THIERRY·Filed 2007·Granted Apr 29, 2014·0 cites·11 claims
- 3666US2019135916A1Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune diseaseIMMUTEP·Filed 2018·Application pending·0 cites
- 3765US6114516ANucleotide sequences coding for variable regions of the αchains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic musesHOECHST MARION ROUSSEL INC·Filed 1998·Granted Sep 5, 2000·16 cites·4 claims
- 3864US5798231ANucleotide sequences for α chain variable regions in human lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic usesROUSSEL UCLAF·Filed 1996·Granted Aug 25, 1998·15 cites·9 claims
- 3964US2025368714A1Treatment of cancerIMMUTEP SAS·Filed 2023·Application pending·0 cites
- 4063US5817511ANucleotide sequence coding for variable regions of the α chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic usesROUSSEL UCLAF·Filed 1995·Granted Oct 6, 1998·15 cites·6 claims
- 4161US2024277804A1Triple combination therapyIMMUTEP SAS·Filed 2022·Application pending·0 cites
- 4260US5830758AIsolated Vβ TCR antibodiesROUSSEL UCLAF·Filed 1995·Granted Nov 3, 1998·13 cites·2 claims
- 4356US2016176965A1Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune diseaseIMMUTEP PARC CLUB ORSAY·Filed 2015·Application pending·0 cites
- 4455US6596536B1Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic usesAVENTIS PHARMA SA·Filed 1995·Granted Jul 22, 2003·20 cites·6 claims
- 4555US2023210946A1Treatment of cancerIMMUTEP SAS·Filed 2021·Application pending·0 cites
- 4653US2015259420A1Antibody molecules to lag-3 and uses thereofNOVARTIS AG·Filed 2015·Application pending·0 cites
- 4751US11680104B2Anti-LAG-3 antibodiesIMMUTEP SAS·Filed 2016·Granted Jun 20, 2023·0 cites·7 claims
- 4851US2022220199A1Anti-lag-3 binding moleculesIMMUTEP SAS·Filed 2020·Application pending·0 cites
- 4950US2022341913A1AssaysIMMUTEP SAS·Filed 2020·Application pending·0 cites
- 5046US2004171551A1Molecules binding to Glu-Pro motifs, therapeutic compositions containing them and their applicationsINST GUSTAVE ROUSSY IGR A CORP·Filed 2004·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Frederic Triebel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →